Online inquiry

IVTScrip™ mRNA-Anti-MS4A1, IMMU-106(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9222MR)

This product GTTS-WQ9222MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets MS4A1 gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001048028.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 485430
UniProt ID Q3C2E2
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MS4A1, IMMU-106(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ9222MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4365MR IVTScrip™ mRNA-Anti-B7, BMS-188667(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BMS-188667
GTTS-WQ10394MR IVTScrip™ mRNA-Anti-TNFSF13B, LY2127399(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LY2127399
GTTS-WQ8926MR IVTScrip™ mRNA-Anti-IL1B, IL-1 Trap(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IL-1 Trap
GTTS-WQ999MR IVTScrip™ mRNA-Anti-SLAMF7, ABBV-383(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-383
GTTS-WQ5521MR IVTScrip™ mRNA-Anti-IL17A&IL17F, CDP4940(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CDP4940
GTTS-WQ2774MR IVTScrip™ mRNA-Anti-IL1RL1, AMG-282(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG-282
GTTS-WQ4767MR IVTScrip™ mRNA-Anti-TNFSF13B, BR3-Fc(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BR3-Fc
GTTS-WQ10848MR IVTScrip™ mRNA-Anti-FOLR1, M9346A(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA M9346A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW